Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's Esophagus

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 4, 2015, Pages 665-672.e4

  Chak, Amitabh ^a   Buttar, Navtej S ^b   Foster, Nathan R ^b   Seisler, Drew K ^b   Marcon, Norman E ^b   Schoen, Robert ^c   Cruz Correa, Marcia R ^d   Falk, Gary W ^e   Sharma, Prateek ^f   Hur, Chin ^g   Katzka, David A ^h   Rodriguez, Luz M ⁱ   Richmond, Ellen ⁱ   Sharma, Anamay N ^b   Smyrk, Thomas C ^b   Mandrekar, Sumithra J ^b   Limburg, Paul J ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b MAYO CLINIC   (United States)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g Hepatology and Motility ^*  (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer Development; Diabetes Drug; HOMA IR; Tumorigenesis

Indexed keywords

CASPASE 3; INSULIN; METFORMIN; PLACEBO; S6 KINASE;

ABDOMINAL PAIN; ADULT; AGED; AMNESIA; APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; ENZYME PHOSPHORYLATION; ESOPHAGOGASTRODUODENOSCOPY; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; BLOOD; COMPLICATION; DIGESTIVE TRACT ENDOSCOPY; DRUG EFFECTS; ESOPHAGEAL NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; CELL PROLIFERATION; DOUBLE-BLIND METHOD; ENDOSCOPY, DIGESTIVE SYSTEM; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; INSULIN; MALE; METFORMIN; MIDDLE AGED; PLACEBOS; PROSPECTIVE STUDIES; RIBOSOMAL PROTEIN S6 KINASES; YOUNG ADULT;

EID: 84924955218     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.08.040     Document Type: Article

References (43)

1. Calle E.E. Obesity and cancer. BMJ 2007, 335:1107-1108.
2. Calle E.E., Teras L.R., Thun M.J. Obesity and mortality. NEngl J Med 2005, 353:2197-2199.
3. Calle E.E., Thun M.J. Obesity and cancer. Oncogene 2004, 23:6365-6378.
4. Calle E.E., Rodriguez C., Walker-Thurmond K., et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. NEngl J Med 2003, 348:1625-1638.
5. Calle E.E., Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms-nature reviews. Cancer 2004, 4:579-591.
6. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia: nature reviews. Cancer 2008, 8:915-928.
7. Giovannucci E., Pollak M.N., Platz E.A., et al. Aprospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 2000, 9:345-349.
8. Pollak M. Insulin-like growth factor physiology and neoplasia. Growth Horm IGF Res 2000, 10(Suppl A):S6-S7.
9. Singh S., Sharma A.N., Murad M.H., et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013, 11:1399-1412.
10. Greer K.B., Thompson C.L., Brenner L., et al. Association of insulin and insulin-like growth factors with Barrett's oesophagus. Gut 2012, 61:665-672.
11. Neale R.E., Doecke J.D., Pandeya N., et al. Does type 2 diabetes influence the risk of oesophageal adenocarcinoma?. Br J Cancer 2009, 100:795-798.
12. Towler M.C., Hardie D.G. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007, 100:328-341.
13. Landman G.W., Kleefstra N., van Hateren K.J., et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010, 33:322-326.
14. Grenader T., Goldberg A., Shavit L. Metformin as an addition to conventional chemotherapy in breast cancer. JClin Oncol 2009, 27:e259. author reply e260.
15. Hirsch H.A., Iliopoulos D., Tsichlis P.N., et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009, 69:7507-7511.
16. Zakikhani M., Dowling R., Fantus I.G., et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006, 66:10269-10273.
17. Evans J.M., Donnelly L.A., Emslie-Smith A.M., et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005, 330:1304-1305.
18. Li D., Yeung S.C., Hassan M.M., et al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009, 137:482-488.
19. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
20. Sharma P., Dent J., Armstrong D., et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology 2006, 131:1392-1399.
21. Pocock S.J., Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975, 31:103-115.
22. Spechler S.J., Sharma P., et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 2011, 140:1084-1091. American Gastroenterological Association.
23. Wang K.K., Sampliner R.E. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008, 103:788-797.
24. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
25. Nguyen D.M., Richardson P., El-Serag H.B. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology 2010, 138:2260-2266.
26. Corley D.A., Kerlikowske K., Verma R., et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003, 124:47-56.
27. Falk G.W., Buttar N.S., Foster N.R., et al. Acombination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus. Gastroenterology 2012, 143:917-926.
28. Khandekar M.J., Cohen P., Spiegelman B.M. Molecular mechanisms of cancer development in obesity: nature reviews. Cancer 2011, 11:886-895.
29. Duggan C., Onstad L., Hardikar S., et al. Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2013, 11:934-943.
30. Iyer P.G., Borah B.J., Heien H.C., et al. Association of Barrett's esophagus with type II diabetes mellitus: results from a large population-based case-control study. Clin Gastroenterol Hepatol 2013, 11:1108-1114.
31. Ryan A.M., Healy L.A., Power D.G., et al. Barrett esophagus: prevalence of central adiposity, metabolic syndrome, and a proinflammatory state. Ann Surg 2008, 247:909-915.
32. Garcia J.M., Splenser A.E., Kramer J., et al. Circulating inflammatory cytokines and adipokines are associated with increased risk of Barrett's esophagus: a case-control study. Clin Gastroenterol Hepatol 2014, 12:229-238.
33. Fujita T. Adiponectin and Barrett's esophagus. Am J Gastroenterol 2009, 104:243. author reply 244-245.
34. Kendall B.J., Macdonald G.A., Hayward N.K., et al. Leptin and the risk of Barrett's oesophagus. Gut 2008, 57:448-454.
35. Mokrowiecka A., Daniel P., Jasinska A., et al. Serum adiponectin, resistin, leptin concentration and central adiposity parameters in Barrett's esophagus patients with and without intestinal metaplasia in comparison to healthy controls and patients with GERD. Hepatogastroenterology 2012, 59:2395-2399.
36. Rubenstein J.H., Dahlkemper A., Kao J.Y., et al. Apilot study of the association of low plasma adiponectin and Barrett's esophagus. Am J Gastroenterol 2008, 103:1358-1364.
37. Rubenstein J.H., Kao J.Y., Madanick R.D., et al. Association of adiponectin multimers with Barrett's oesophagus. Gut 2009, 58:1583-1589.
38. Thompson O.M., Beresford S.A., Kirk E.A., et al. Serum leptin and adiponectin levels and risk of Barrett's esophagus and intestinal metaplasia of the gastroesophageal junction. Obesity 2010, 18:2204-2211.
39. Singh S., Singh A.G., Singh P.P., et al. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013, 11:620-629.
40. Yen C.J., Izzo J.G., Lee D.F., et al. Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma. Cancer Res 2008, 68:2632-2640.
41. Kargman S., Charleson S., Cartwright M., et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 1996, 111:445-454.
42. Buttar N.S., Wang K.K., Leontovich O., et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002, 122:1101-1112.
43. Buttar N.S., Wang K.K., Sebo T.J., et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001, 120:1630-1639.